Sylvie Lorenzen

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 8

Top Topics

Epidermal Growth Factor Receptor

Diffusion Weighted

Top Venues

International journal of cancer

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Michael Masetti, Salah-Eddin Al-Batran, Thorsten O Goetze, Peter Thuss-Patience, Jorge Riera Knorrenschild, Eray Goekkurt, Gunnar Folprecht, Thomas Jens Ettrich, Udo Lindig, Kim Barbara Luley, Daniel Pink, Tobias Dechow, Disorn Sookthai, Sabine Junge, Maria Loose, Claudia Pauligk, Sylvie Lorenzen
Efficacy of ramucirumab combination chemotherapy as second-line treatment in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction after exposure to checkpoint inhibitors and chemotherapy as first-line therapy. International journal of cancer (2024)
Michael Masetti, Salah-Eddin Al-Batran, Thorsten O Goetze, Peter Thuss-Patience, Jorge Riera Knorrenschild, Eray Goekkurt, Gunnar Folprecht, Thomas Jens Ettrich, Udo Lindig, Kim Barbara Luley, Daniel Pink, Tobias Dechow, Disorn Sookthai, Sabine Junge, Maria Loose, Claudia Pauligk, Sylvie Lorenzen
Efficacy of ramucirumab combination chemotherapy as second-line treatment in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction after exposure to checkpoint inhibitors and chemotherapy as first-line therapy. International journal of cancer 154 (12) (2024)
Magdalena K Scheck, Ralf-Dieter Hofheinz, Sylvie Lorenzen
HER2-Positive Gastric Cancer and Antibody Treatment: State of the Art and Future Developments. Cancers 16 (7) (2024)
Magdalena K Scheck, Ralf-Dieter Hofheinz, Sylvie Lorenzen
HER2-Positive Gastric Cancer and Antibody Treatment: State of the Art and Future Developments. Cancers 16 (7) (2024)
Michael Masetti, Salah-Eddin Al-Batran, Thorsten O Goetze, Peter Thuss-Patience, Jorge Riera Knorrenschild, Eray Goekkurt, Gunnar Folprecht, Thomas Jens Ettrich, Udo Lindig, Kim Barbara Luley, Daniel Pink, Tobias Dechow, Disorn Sookthai, Sabine Junge, Maria Loose, Claudia Pauligk, Sylvie Lorenzen
Efficacy of ramucirumab combination chemotherapy as second-line treatment in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction after exposure to checkpoint inhibitors and chemotherapy as first-line therapy. International journal of cancer 154 (12) (2024)
Magdalena K Scheck, Ralf-Dieter Hofheinz, Sylvie Lorenzen
HER2-Positive Gastric Cancer and Antibody Treatment: State of the Art and Future Developments. Cancers 16 (7) (2024)
Sylvie Lorenzen, Thorsten Oliver Götze, Peter C Thuss-Patience, Matthias Biebl, Nils Homann, Michael Schenk, Udo Lindig, Vera Heuer, Albrecht Kretzschmar, Eray Goekkurt, Georg Martin Haag, Jorge Riera-Knorrenschild, Claus Bolling, Ralf-Dieter Hofheinz, Tianzuo Zhan, Stefan Angermeier, Thomas Jens Ettrich, Alexander Reinhard Siebenhüner, Moustafa Elshafei, Wolf Otto Bechstein, Timo Gaiser, Maria Loose, Disorn Sookthai, Christina Kopp, Claudia Pauligk, Salah-Eddin Al-Batran, null null
Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Sylvie Lorenzen, Jorge Riera Knorrenschild, Claudia Pauligk, Susanna Hegewisch-Becker, Jörg Seraphin, Peter Thuss-Patience, Hans-Georg Kopp, Tobias Dechow, Arndt Vogel, Kim Barbara Luley, Daniel Pink, Michael Stahl, Frank Kullmann, Holger Hebart, Jens Thomas Siveke, Matthias Egger, Nils Homann, Stephan Probst, Thorsten Oliver Goetze, Salah-Eddin Al-Batran
Phase III randomized, double-blind study of paclitaxel with and without everolimus in patients with advanced gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC). International journal of cancer 147 (9) (2020)